FNY Investment Advisers’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26K Hold
14,000
0.01% 498
2026
Q1
$54K Hold
14,000
0.02% 355
2025
Q4
$27K Hold
14,000
0.01% 531
2025
Q3
$11K Hold
14,000
﹤0.01% 786
2025
Q2
$10K Buy
14,000
+10,000
+250% +$7.51K ﹤0.01% 662
2025
Q1
$3K Hold
4,000
﹤0.01% 623
2024
Q4
$6K Buy
+4,000
New +$9.57K ﹤0.01% 526
2022
Q3
Sell
-25,600
Closed -$68K 761
2022
Q2
$68K Sell
25,600
-6,040
-19% -$22.5K 0.05% 200
2022
Q1
$137K Buy
31,640
+19,040
+151% +$78.2K 0.13% 140
2021
Q4
$65K Buy
+12,600
New +$67.4K 0.03% 238
2021
Q3
Sell
-5,000
Closed -$50K 846
2021
Q2
$50K Buy
+5,000
New +$54.2K 0.02% 417

Other funds holding NAUT

FNY Investment Advisers's NAUT Position: Q2 2026 in Review

FNY Investment Advisers held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 14,000 shares worth $26K. The position accounts for 0.01% of the portfolio, ranked #498.

FNY Investment Advisers first reported a position in NAUT in Q2 2021 and has held it in 11 quarters since. The position peaked at $137K in Q1 2022. 17 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • FNY Investment Advisers held 14,000 shares of Nautilus Biotechnolgy worth $26K as of Q2 2026.
  • FNY Investment Advisers left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #498 holding.
  • FNY Investment Advisers first reported a position in Nautilus Biotechnolgy in Q2 2021 and has held it in 11 quarters since.
  • FNY Investment Advisers's Nautilus Biotechnolgy position peaked at $137K in Q1 2022.
  • 17 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.